Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Andrew J SaxonSarah C AkermanChih-Chin LiuMaria A SullivanBernard L SilvermanFrank J VocciPublished in: Addiction (Abingdon, England) (2018)
Among opioid-dependent people receiving XR-NTX treatment, better mental health, higher education and lower recent drug use at baseline are associated with greater treatment duration; in turn, longer treatment duration is associated with lower relapse rates and improved outcomes generally.